Lian Weibin, Zheng Juanjuan, Chen Debo
Department of Breast Surgery, The Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, China.
Department of Medical-Records, The Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, China.
Transl Cancer Res. 2020 Oct;9(10):5969-5978. doi: 10.21037/tcr-20-1237.
Our study aims to investigate the clinicopathological characteristics and survival outcomes of mucinous breast cancer (MBC), and explore the effect of histology type on the breast cancer-specific survival (BCSS) by different subtypes.
we identified 7,083 patients who were diagnosed with MBC and 248,751 with infiltrating ductal carcinoma (IDC) by using the Surveillance, Epidemiology and End Results (SEER) database. The propensity score matching was used to match baseline characteristics among MBC and IDC, and multivariable cox proportional hazards models were used to analyze the relationship between histology type stratified by subtype and BCSS.
MBC patients were associated with a fewer nodal involvement, lower grade, earlier stage, more estrogen receptor (ER) or progesterone receptor (PR) positive, and more favorable prognosis compared to the overall IDC population. After 1:1 matching of MBC with IDC by other factors, we found that MBC patients presented better prognosis than the Matched IDC for BCSS. Analysis among ER+PR+ subgroup revealed that MBC patients was significantly better than that Matched IDC patients for BCSS (HR =0.78, 95% CI, 0.63-0.96). However, the survival analysis in the ER+PR- or ER-PR- subgroups suggested that no significant difference was seen between MBC patients and matched IDC patients for BCSS.
Our findings support that MBC seems to be an independent factor for the better prognosis for breast cancer patients with ER+PR+ breast cancer but not in those with ER+PR- or ER-PR- disease.
我们的研究旨在调查黏液性乳腺癌(MBC)的临床病理特征和生存结果,并探讨不同亚型的组织学类型对乳腺癌特异性生存(BCSS)的影响。
我们使用监测、流行病学和最终结果(SEER)数据库,确定了7083例被诊断为MBC的患者和248751例浸润性导管癌(IDC)患者。采用倾向评分匹配法对MBC和IDC患者的基线特征进行匹配,并使用多变量Cox比例风险模型分析按亚型分层的组织学类型与BCSS之间的关系。
与总体IDC人群相比,MBC患者的淋巴结受累较少、分级较低、分期较早、雌激素受体(ER)或孕激素受体(PR)阳性率较高,预后较好。在按其他因素对MBC与IDC进行1:1匹配后,我们发现MBC患者的BCSS预后优于匹配的IDC患者。在ER+PR+亚组的分析中显示,MBC患者的BCSS明显优于匹配的IDC患者(HR=0.78,95%CI,0.63-0.96)。然而,ER+PR-或ER-PR-亚组的生存分析表明,MBC患者与匹配的IDC患者在BCSS方面没有显著差异。
我们的研究结果支持,MBC似乎是ER+PR+乳腺癌患者预后较好的独立因素,但对于ER+PR-或ER-PR-疾病患者并非如此。